DiaSorin Delivering on Covid Capacity Expansion, Recovery Underway For Core Disease Testing

DiaSorin is a niche player in the fragmented in vitro diagnostic market with diagnostic specialization in infectious diseases. Its systems are able to perform tests for diseases such as hepatitis, tuberculosis, mumps, and measles. The firm maintains a nearly 20% market share in immunodiagnostics and a 12% share in the highly competitive molecular diagnostics market. Despite operating in a competitive industry with high research requirements, DiaSorin has consistently been able to expand its installed base and deliver moatworthy returns for shareholders over time.